GSK plc GSK announced that the FDA has granted a Breakthrough Therapy Designation to its investigational B7-H3-targeted ...

The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tutors ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...

GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Shares of CytomX Therapeutics (NASDAQ:CTMX) fell on Tuesday after the cancer drug developer announced a roughly 40% reduction ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

GSK plc (GSK, GSK.L) said that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for GSK5764227, its ...